DAIGO YATARO has a total of 13 patent applications. Its first patent ever was published in 2005. It filed its patents most often in WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are CONSORTIUM NAT DE RECH EN GENO, DRK BLUTSPENDEDIENST BW and FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 13 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Measuring microorganism processes | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Analysing materials | |
#5 | Medical preparations | |
#6 | Peptides | |
#7 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Nakamura Yusuke | 13 |
#2 | Daigo Yataro | 13 |
#3 | Tsunoda Takuya | 8 |
#4 | Nakatsuru Shuichi | 6 |
#5 | Tahara Hideaki | 1 |
Publication | Filing date | Title |
---|---|---|
WO2012023290A1 | Rasef as tumor marker and therapeutic target for cancer | |
WO2012023288A1 | Fam161a as a target gene for cancer therapy and diagnosis | |
WO2012023286A1 | Lrrc42 as a target gene for cancer therapy and diagnosis | |
WO2011161960A1 | C1orf59 for target genes of cancer therapy and diagnosis | |
WO2011024433A1 | Lung and esophageal cancer related gene adamts18 | |
WO2011021386A1 | Cstf2 for target genes of lung cancer therapy and diagnosis | |
WO2006090810A2 | Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides |